left-arrow right-arrow pinterest facebook google_plus linkedin

Alliance A041702


Recruiting | Phase III 

Official Title:

A Randomized Phase III study of Ibrutinib Plus Obinutuzumab versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 years of age) with Chronic Lymphocytic Leukemia (CLL)

Study Purpose:

To compare the usual treatment alone (Ibrutinib plus Obinutuzumab) to using Venetoclax plus the usual treatment. The addition of Venetoclax to the usual treatment could prevent chronic lymphocytic leukemia from returning.


  • Group 1: Ibrutinib plus Obinutuzumab
  • Group 2: Ibrutinib plus Obinutuzumab plus Venetoclax (study drug)

Key Participation Requirements:


Male or Female


≥ 70 years


Chronic Lymphocytic Leukemia


Confirmed Chronic Lymphocytic Leukemia diagnosis.

Central FISH blood submission.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

Alliance A041702

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!